Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
Destaques regulatrios: Diversos agonistas de GLP-1 j esto aprovados pela Anvisa , com indicao para diabetes tipo 2 Em 2023, a Anvisa aprovou a semaglutida injetvel (nome comercial Wegovy) para obesidade Algumas verses esto disponveis no SUS via Protocolos Clnicos e Diretrizes Teraputicas (PCDTs) , mas com critrios restritivos O uso para emagrecimento ainda foco de debates sobre judicializao e prescrio racional Riscos, efeitos adversos e controvrsias Apesar dos benefcios teraputicos significativos, os medicamentos base de GLP-1 no esto isentos de efeitos colaterais e desafios clnicos
Vem ska inte ta GLP-1-lkemedel
For weight management specifically, the FDA has approved several GLP-1 medications at higher doses than those used for diabetes treatment
Wondering what these medications doand why theyre receiving so much attention
He suggested it after demonstrating that the glucose-lowering substance was derived from the islets (Harris)